Targeting the epigenome and immune evasion: a new chapter in PRMT5 inhibition

Ann Oncol. 2025 Dec;36(12):1431-1432. doi: 10.1016/j.annonc.2025.09.014. Epub 2025 Nov 3.

Authors

P A Shah¹, J Rodon²

Affiliations

¹ Investigational Cancer Therapeutics, The University of Texas at MD Anderson Cancer Center, Houston 77030, USA.
² Investigational Cancer Therapeutics, The University of Texas at MD Anderson Cancer Center, Houston 77030, USA. Electronic address: jrodon@mdanderson.org.

PMID: 41188151
DOI: 10.1016/j.annonc.2025.09.014

No abstract available

Publication types

Editorial